BRTX logo

BioRestorative Therapies (BRTX) Cash From Financing

Annual CFF

$2.35 M
+$2.35 M+100.00%

December 1, 2023

Summary

Performance

1-Year Change

+100%

3-Year Change

-53.23%

5-Year Change

-50.84%

15-Year Change

-45.03%

BRTX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

41.44%
BRTX annual cash flow from financing activities is higher than 41.44% of companies in Healthcare sector

High & Low

All-time High

$21.32 M
BRTX annual cash flow from financing activities is currently -88.97% below its historical high of $21.32 million

3-Year Low

$0.00
BRTX annual cash flow from financing activities is currently >+9900.00% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2023
BRTX previous annual earnings announcement was published on Dec 1, 2023

Next Annual Earnings Report Date

N/A
BRTX next annual earnings announcement has not yet been scheduled

OtherBRTXcash flowmetrics:

Annual CFI

$3.25 M
BRTX annual cash flow from investing activities is $3.25 million

Annual CFO

-$6.43 M
BRTX annual cash flow from operations is -$6.43 million

Annual FCF

-$6.60 M
BRTX annual free cash flow is -$6.60 million

Annual CAPEX

$171.00 K
BRTX annual capital expenditures is $171.00 thousand

Quarterly CFF

$0.00
+$12.80 K+100.00%

September 1, 2024

Summary

Performance

3-Month Change

+100%

1-Year Change

-100%

3-Year Change

-100%

5-Year Change

-100%

BRTX Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

45.62%
BRTX quarterly cash flow from financing activities is higher than 45.62% of companies in Healthcare sector

High & Low

All-time High

$21.07 M
BRTX quarterly cash flow from financing activities is currently -100.00% below its historical high of $21.07 million

3-Year Low

-$12.80 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
BRTX previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
BRTX next earnings announcement has not yet been scheduled

OtherBRTXcash flowmetrics:

Quarterly CFI

$936.80 K
BRTX quarterly cash flow from investing activities is $936.80 thousand

Quarterly CFO

-$1.70 M
BRTX quarterly cash flow from operations is -$1.70 million

Quarterly FCF

-$1.76 M
BRTX quarterly free cash flow is -$1.76 million

Quarterly CAPEX

$58.50 K
BRTX quarterly capital expenditures is $58.50 thousand

TTM CFF

$7.59 M
-$1.85 M-19.63%

September 1, 2024

Summary

Performance

3-Month Change

-19.63%

1-Year Change

+234.94%

3-Year Change

-64.41%

5-Year Change

-64.41%

BRTX TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

48.95%
BRTX TTM cash flow from financing activities is higher than 48.95% of companies in Healthcare sector

High & Low

All-time High

$21.32 M
BRTX TTM cash flow from financing activities is currently -64.41% below its historical high of $21.32 million

3-Year Low

$0.00
BRTX TTM cash flow from financing activities is currently >+9900.00% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2024
BRTX previous earnings announcement was published on Sep 1, 2024

Next Quarterly Earnings Report Date

N/A
BRTX next earnings announcement has not yet been scheduled

OtherBRTXcash flowmetrics:

TTM CFI

-$1.10 M
BRTX TTM cash flow from investing activities is -$1.10 million

TTM CFO

-$7.47 M
BRTX TTM cash flow from operations is -$7.47 million

TTM FCF

-$7.63 M
BRTX TTM free cash flow is -$7.63 million

TTM CAPEX

$163.80 K
BRTX TTM capital expenditures is $163.80 thousand

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

BRTX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+100.0%-100.0%+234.9%
3 y3 years-53.2%-100.0%-64.4%
5 y5 years-50.8%-100.0%-64.4%

BRTX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-89.0%-100.0%-100.0%+100.0%-64.4%-100.0%
5 y5-year-89.0%-100.0%-100.0%+100.0%-64.4%-100.0%
alltimeall time-89.0%-100.0%-100.0%+100.0%-64.4%-100.0%

BioRestorative Therapies Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$0.00(-100.0%)
$7.59 M(-19.6%)
Jun 2024
-
-$12.80 K(-100.2%)
$9.44 M(-4.3%)
Mar 2024
-
$7.52 M(+8947.5%)
$9.87 M(+320.1%)
Dec 2023
$2.35 M(>+9900.0%)
$83.10 K(-95.5%)
$2.35 M(+3.7%)
Sep 2023
-
$1.85 M(+350.3%)
$2.27 M(+450.3%)
Jun 2023
-
$411.70 K(>+9900.0%)
$411.70 K(>+9900.0%)
Mar 2023
-
$0.00(0.0%)
$0.00(0.0%)
Dec 2022
$0.00(-100.0%)
$0.00(0.0%)
$0.00(-100.0%)
Sep 2022
-
$0.00(0.0%)
$21.07 M(0.0%)
Jun 2022
-
$0.00(0.0%)
$21.07 M(0.0%)
Mar 2022
-
$0.00(-100.0%)
$21.07 M(-1.2%)
Dec 2021
$21.32 M(+324.1%)
$21.07 M(>+9900.0%)
$21.32 M(+474.6%)
Sep 2021
-
$0.00(0.0%)
$3.71 M(-9.8%)
Jun 2021
-
$0.00(-100.0%)
$4.11 M(-14.8%)
Mar 2021
-
$250.00 K(-92.8%)
$4.83 M(-4.0%)
Dec 2020
$5.03 M(-26.5%)
$3.46 M(+763.0%)
$5.03 M(+53.2%)
Sep 2020
-
$401.00 K(-43.8%)
$3.28 M(-3.8%)
Jun 2020
-
$713.80 K(+58.0%)
$3.41 M(-30.8%)
Mar 2020
-
$451.80 K(-73.6%)
$4.93 M(-27.9%)
Dec 2019
$6.84 M(+43.0%)
$1.71 M(+222.7%)
$6.84 M(+2.2%)
Sep 2019
-
$531.30 K(-76.2%)
$6.69 M(-12.1%)
Jun 2019
-
$2.23 M(-5.3%)
$7.61 M(+18.4%)
Mar 2019
-
$2.36 M(+50.7%)
$6.43 M(+34.4%)
Dec 2018
$4.78 M(+11.8%)
$1.57 M(+7.6%)
$4.78 M(-4.9%)
Sep 2018
-
$1.45 M(+38.8%)
$5.03 M(+23.2%)
Jun 2018
-
$1.05 M(+46.6%)
$4.09 M(+7.6%)
Mar 2018
-
$715.10 K(-60.6%)
$3.80 M(-11.2%)
Dec 2017
$4.28 M
$1.81 M(+257.1%)
$4.28 M(+20.3%)
DateAnnualQuarterlyTTM
Sep 2017
-
$508.00 K(-33.1%)
$3.56 M(-5.8%)
Jun 2017
-
$759.00 K(-36.5%)
$3.78 M(-11.3%)
Mar 2017
-
$1.20 M(+9.3%)
$4.26 M(-15.8%)
Dec 2016
$5.06 M(+37.4%)
$1.09 M(+50.6%)
$5.06 M(-3.1%)
Sep 2016
-
$726.50 K(-41.5%)
$5.22 M(-1.4%)
Jun 2016
-
$1.24 M(-37.7%)
$5.29 M(+10.7%)
Mar 2016
-
$1.99 M(+58.8%)
$4.78 M(+29.8%)
Dec 2015
$3.68 M(+12.0%)
$1.26 M(+57.2%)
$3.68 M(+25.0%)
Sep 2015
-
$798.50 K(+9.4%)
$2.94 M(-10.7%)
Jun 2015
-
$729.90 K(-18.5%)
$3.29 M(-5.0%)
Mar 2015
-
$896.00 K(+72.7%)
$3.47 M(+5.5%)
Dec 2014
$3.29 M(+13.9%)
$518.90 K(-54.9%)
$3.29 M(-12.2%)
Sep 2014
-
$1.15 M(+27.5%)
$3.74 M(+23.6%)
Jun 2014
-
$902.00 K(+26.2%)
$3.03 M(+30.0%)
Mar 2014
-
$715.00 K(-26.7%)
$2.33 M(-19.2%)
Dec 2013
$2.88 M(-29.9%)
$975.40 K(+124.3%)
$2.88 M(-0.1%)
Sep 2013
-
$434.90 K(+113.2%)
$2.89 M(-3.6%)
Jun 2013
-
$204.00 K(-83.9%)
$3.00 M(-40.8%)
Mar 2013
-
$1.27 M(+29.7%)
$5.06 M(+22.9%)
Dec 2012
$4.12 M(+44.4%)
$978.90 K(+80.5%)
$4.12 M(-4.5%)
Sep 2012
-
$542.40 K(-76.1%)
$4.31 M(+7.3%)
Jun 2012
-
$2.27 M(+597.0%)
$4.02 M(+119.4%)
Mar 2012
-
$325.50 K(-72.2%)
$1.83 M(-35.8%)
Dec 2011
$2.85 M(+258.1%)
$1.17 M(+369.0%)
$2.85 M(+69.9%)
Sep 2011
-
$250.00 K(+200.5%)
$1.68 M(+17.5%)
Jun 2011
-
$83.20 K(-93.8%)
$1.43 M(+6.2%)
Mar 2011
-
$1.34 M
$1.34 M
Dec 2010
$796.00 K
-
-

FAQ

  • What is BioRestorative Therapies annual cash flow from financing activities?
  • What is the all time high annual CFF for BioRestorative Therapies?
  • What is BioRestorative Therapies annual CFF year-on-year change?
  • What is BioRestorative Therapies quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for BioRestorative Therapies?
  • What is BioRestorative Therapies quarterly CFF year-on-year change?
  • What is BioRestorative Therapies TTM cash flow from financing activities?
  • What is the all time high TTM CFF for BioRestorative Therapies?
  • What is BioRestorative Therapies TTM CFF year-on-year change?

What is BioRestorative Therapies annual cash flow from financing activities?

The current annual CFF of BRTX is $2.35 M

What is the all time high annual CFF for BioRestorative Therapies?

BioRestorative Therapies all-time high annual cash flow from financing activities is $21.32 M

What is BioRestorative Therapies annual CFF year-on-year change?

Over the past year, BRTX annual cash flow from financing activities has changed by +$2.35 M (+100.00%)

What is BioRestorative Therapies quarterly cash flow from financing activities?

The current quarterly CFF of BRTX is $0.00

What is the all time high quarterly CFF for BioRestorative Therapies?

BioRestorative Therapies all-time high quarterly cash flow from financing activities is $21.07 M

What is BioRestorative Therapies quarterly CFF year-on-year change?

Over the past year, BRTX quarterly cash flow from financing activities has changed by -$1.85 M (-100.00%)

What is BioRestorative Therapies TTM cash flow from financing activities?

The current TTM CFF of BRTX is $7.59 M

What is the all time high TTM CFF for BioRestorative Therapies?

BioRestorative Therapies all-time high TTM cash flow from financing activities is $21.32 M

What is BioRestorative Therapies TTM CFF year-on-year change?

Over the past year, BRTX TTM cash flow from financing activities has changed by +$5.32 M (+234.94%)